Keele Research Repository

Article

Velikova, G, Williams, LJ, Willis, S, Dixon, JM, Loncaster, J, Hatton, M, Clarke, J, Kunkler, IH, Russell, NS, Alhasso, A, Adamson, D, Algurafi, H, Allerton, R, Anandadas, C, Bahl, A, Barraclough, L, Barrett-Lee, P, Barthakur, U, Bedi, C, Beresford, M, Bishop, J, Blackman, G, Bliss, P, Bloomfield, D, Blunt, M, Branson, T, Brazil, L, Brunt, A, Chakrabarti, A, Chittalie, A, Churn, M, Clarke, J, Cleator, S, Crellin, P, Danwata, F, De-Silva-Minor, S, Dhadda, A, Eicholz, A, Fernando, I, Forrest, J, Fraser, J, Geropantas, K, Goodman, A, Grieve, R, Griffin, M, Hadaki, M, Hall, A, Hatton, M, Hicks, J, Hignett, S, Hogg, M, Jyothirmayi, R, Khan, M, Kumar, S, Lawton, P, Lee, D, Lewinski, C, Lim, C, Locke, I, Loncaster, J, Lumsden, G, Lupton, S, Magee, B, Marshall, J, Masinghe, S, McGregor, C, McLennan, M, Memtsa, P, Milanovic, D, Misra, V, Mithal, N, Mukesh, MB, Neal, A, Needleman, S, Persic, M, Quigley, M, Raj, S, Riddle, P, Ritchie, D, Roberts, F, Robson, P, Roe, H, Rolles, M, Shah, N, Sharma, R, Sherwin, E, Simmonds, P, Skailles, G, Skaria, S, Soe, W, Sripadam, R, Stevens, A, Stockdale, A, Storey, N, Storey, N, Syndikus, I, Thorp, N, Thorp, N, Upadhyay, S, Varughese, M, Walji, N, Welch, R, Wells, T, Wolstenholme, V, Wolstenholme, V, Woodings, P and Yuille, F (2018) Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. The Lancet Oncology, 19 (11). 1516 - 1529.

Earl, HM, Hiller, H, Vallier, A-L, Bowden, SJ, Jordan, SD, Blows, F, Munro, A, Bathers, S, Grieve, R, Spooner, DA, Agrawal, R, Fernando, I, Brunt, AM, O'Reilly, SM, Crawford, SM, Rea, DW, Simmonds, P, Mansi, JL, Stanley, A, McAdam, K, Foster, L, Leonard, RCF, Twelves, CJ, Cameron, D, Bartlett, JMS, Pharoah, P, Provenzano, E, Caldas, C and Poole, CJ (2012) Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. British Journal of Cancer, 107 (8). pp. 1257-1267.